[{"orgOrder":0,"company":"Exela Pharma Sciences, LLC.","sponsor":"Avadel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Neostigmine Methylsulfate","moa":"Acetylcholinesterase","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Exela Pharma Sciences, LLC.","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Exela Pharma Sciences, LLC. \/ Exela Pharma Sciences, LLC.","highestDevelopmentStatusID":"15","companyTruncated":"Exela Pharma Sciences, LLC. \/ Exela Pharma Sciences, LLC."}]

Find Clinical Drug Pipeline Developments & Deals by Exela Pharma Sciences, LLC.

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Company announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™ o Exela Sterile Medicines LLC.

                          Product Name : Bloxiverz

                          Product Type : Other Small Molecule

                          Upfront Cash : $14.5 million

                          January 07, 2020

                          Lead Product(s) : Neostigmine Methylsulfate

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Recipient : Avadel Pharmaceuticals

                          Deal Size : $42.0 million

                          Deal Type : Divestment

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 08, 2018

                          Lead Product(s) : Tranexamic Acid

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          August 13, 2014

                          Lead Product(s) : Ciprofloxacin

                          Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank